Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-06-16 Earnings Release
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Earnings Release Classification · 1% confidence The document is a press release dated June 16, 2019, announcing updated interim efficacy and safety data from the Phase 2 HORIZON trial for the drug melflufen, presented at the EHA Congress. It contains key financial/clinical results (ORR, CBR, safety profiles) and commentary from the CEO and a lead investigator. This structure—announcing key results for a specific reporting period (interim trial data) via a press release—is characteristic of an Earnings Release (ER), which covers periodical financial/operational results, even if the 'period' here is a clinical trial update rather than a standard fiscal quarter. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), a Call Transcript (CT), or a formal Audit Report (AR). Since it is the initial announcement of key results, ER is the most appropriate classification. FY 2019
2019-06-16 English
New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
Regulatory Filings Classification · 1% confidence The document is a press release dated June 14, 2019, announcing new data from clinical trials (ANCHOR and O-12-M1) evaluating the drug Melflufen, which was presented at the 24th EHA Congress. It includes detailed efficacy and safety data summaries, quotes from the CEO and doctors, and information about ongoing and future trials (HORIZON, OCEAN). This content structure—announcing clinical trial results and scientific presentations via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is primarily focused on communicating recent scientific/clinical progress and business updates rather than being a formal, comprehensive financial report (like 10-K or IR) or a transcript of a call, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the context of presenting new data, it functions as a key business update. However, the definitions suggest ER is for 'initial announcement of quarterly/periodical financial results (key highlights only)'. This document is about clinical trial data presentation, not financial results highlights. Therefore, the most appropriate general category for a non-standard, timely corporate announcement detailing scientific progress is Regulatory Filings (RNS), as it is a formal communication to the market that doesn't fit the other specific categories like DIV, CAP, or ER (which focuses on financial results). It is not a Report Publication Announcement (RPA) because it contains the substance of the findings, not just a notice that a report is available.
2019-06-14 English
Oncopeptides presenterar nya data från fas 1/2-studien ANCHOR med melflufen i RRMM-patienter vid det 24:e europeiska hematologimötet (EHA)
Earnings Release Classification · 1% confidence The document is a press release dated June 14, 2019, announcing that Oncopeptides will present new data from its ANCHOR and O-12-M1 clinical studies at the 24th European Hematology Association (EHA) congress. It details the study results (efficacy, safety) and includes quotes from management and investigators. Crucially, it states that the full posters are available on the company's website and that the information is being made public under EU Market Abuse Regulation. This structure—announcing data presentation and providing key highlights in a press release format—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is primarily focused on communicating clinical trial results and updates rather than a formal, comprehensive financial report (like 10-K or IR), and it is a direct announcement of results/events, ER is the most appropriate fit for clinical/scientific updates released via press release. It is not a transcript (CT), a formal report (10-K/IR), or just an announcement of a report's publication (RPA). FY 2019
2019-06-14 Swedish
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled 'KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)' which translates to 'COMMUNIQUÉ FROM THE ANNUAL GENERAL MEETING OF ONCOPEPTIDES AB (PUBL)'. It details the key decisions made during the 2019 AGM, including the approval of the annual report, election of board members, and approval of incentive programs. This content directly corresponds to the purpose of an AGM-related document, specifically reporting the outcomes of the meeting. Therefore, the classification is AGM-R.
2019-05-21 Swedish
BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled 'BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)' and details the resolutions passed at the meeting held on May 21, 2019. Key actions mentioned include the adoption of the annual report, approval of remunerations, re-election of board members, and the introduction of incentive programs. This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-21 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q1 2019' and contains comprehensive financial statements, a CEO statement, clinical trial updates, and a financial overview for the period January 1 to March 31, 2019. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2019
2019-05-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.